https://www.selleckchem.com/pr....oducts/Nafamostat-me
i.d. Disease Activity Score in 28 Joints-C-reactive protein (DAS28-CRP) scores, ACR20/50/70 response, and rates of low disease activity and remission were similar between placebo and GSK2982772 arms. These results suggest that inhibition of RIPK1 activity at the GSK2982772 exposure levels evaluated do not translate into meaningful clinical improvement of RA. ClinicalTrials.gov Identifier NCT02858492 . Registered 8 August 2016. ClinicalTrials.gov Identifier NCT02858492 . Registered 8 August 2016. Understanding the molecular a
Like
Comment
Share
